{"hands_on_practices": [{"introduction": "Pathogens are under intense selective pressure to neutralize the host's first lines of defense, such as the complement system. This exercise models a sophisticated evasion strategy where a pathogen recruits a host's own regulatory protein, Factor H, to protect itself from opsonization by C3b. By working through this problem [@problem_id:2879447], you will develop a quantitative understanding of how accelerating the decay of an immune effector can dramatically alter its steady-state abundance on a pathogen's surface, providing a powerful survival advantage.", "problem": "A pathogen cloaks itself from the complement system by recruiting human complement factor H to its surface. Consider the deposition and removal of complement component C3b on a small, approximately planar patch of the pathogen surface. Let the surface number density of C3b at time $t$ be $N(t)$, measured in molecules per unit area. Assume the following minimal, mass-action surface balance model grounded in core immunological and biochemical principles.\n\n- Deposition: C3b is deposited onto the patch at a constant rate (flux) $\\alpha$ due to ongoing complement activation in the fluid phase, with units of molecules per unit area per unit time. Assume that recruitment of factor H does not change $\\alpha$ on the time scale considered.\n- Removal (inactivation): In the absence of factor H, surface-bound C3b is inactivated to inactive C3b (iC3b) through factor I at an effective pseudo-first-order rate with rate constant $k$, yielding an exponential decay of $N(t)$ when deposition ceases. The empirical half-life of C3b under these conditions is $t_{1/2}$, which is related to $k$ by the definition of half-life for exponential decay. When factor H is recruited and bound, it acts as a cofactor for factor I and increases the inactivation rate so that the effective half-life is reduced to $t_{1/2}'$ (with $t_{1/2}' < t_{1/2}$), corresponding to a modified rate constant $k'$.\n\nAssume that a steady state is reached in both conditions (without and with factor H bound), at which the deposition rate balances the removal rate.\n\nDefine the fold-change $F$ in the steady-state C3b density due to factor H binding as $F = N_{\\mathrm{ss}}'/N_{\\mathrm{ss}}$, where $N_{\\mathrm{ss}}$ and $N_{\\mathrm{ss}}'$ are the steady-state densities without and with factor H bound, respectively.\n\nUsing only (i) the mass-balance principle for a well-mixed surface patch, (ii) the definition of steady state, and (iii) the definition of half-life for exponential decay, derive a closed-form expression for $F$ in terms of $t_{1/2}$ and $t_{1/2}'$. Provide your final expression for $F$ in simplest form. The final answer must be a single analytic expression without units. Do not approximate or round.", "solution": "The problem as stated is scientifically grounded, well-posed, and contains sufficient information for a unique solution. I shall proceed with the derivation.\n\nLet $N(t)$ represent the surface number density of C3b molecules on the pathogen surface at time $t$. The dynamics of $N(t)$ are governed by a mass-balance equation, which states that the rate of change of the density is equal to the rate of deposition minus the rate of removal.\n$$ \\frac{dN(t)}{dt} = \\text{Rate}_{\\text{deposition}} - \\text{Rate}_{\\text{removal}} $$\nAccording to the problem statement, the deposition occurs at a constant rate, or flux, $\\alpha$.\n$$ \\text{Rate}_{\\text{deposition}} = \\alpha $$\nThe removal process is described as a pseudo-first-order reaction, meaning its rate is directly proportional to the current surface density $N(t)$.\n$$ \\text{Rate}_{\\text{removal}} = k_{\\mathrm{eff}} N(t) $$\nHere, $k_{\\mathrm{eff}}$ is the effective pseudo-first-order rate constant, which depends on the presence of factor H. Combining these terms, we obtain the governing ordinary differential equation:\n$$ \\frac{dN(t)}{dt} = \\alpha - k_{\\mathrm{eff}} N(t) $$\nAt steady state, the surface density is constant, which implies that its time derivative is zero. Let $N_{\\mathrm{ss}}$ denote the steady-state density.\n$$ \\frac{dN}{dt} = 0 $$\nThis condition leads to the balance equation:\n$$ \\alpha - k_{\\mathrm{eff}} N_{\\mathrm{ss}} = 0 $$\nSolving for the steady-state density $N_{\\mathrm{ss}}$ provides a general expression:\n$$ N_{\\mathrm{ss}} = \\frac{\\alpha}{k_{\\mathrm{eff}}} $$\nWe must now apply this general result to the two specific scenarios described.\n\nCase 1: In the absence of factor H.\nThe rate constant is given as $k$, and the steady-state density is $N_{\\mathrm{ss}}$.\n$$ N_{\\mathrm{ss}} = \\frac{\\alpha}{k} $$\nCase 2: In the presence of factor H.\nThe rate constant is given as $k'$, and the steady-state density is $N_{\\mathrm{ss}}'$.\n$$ N_{\\mathrm{ss}}' = \\frac{\\alpha}{k'} $$\nThe problem asks for the fold-change $F$, defined as the ratio $F = N_{\\mathrm{ss}}' / N_{\\mathrm{ss}}$. We can now express $F$ in terms of the rate constants $k$ and $k'$.\n$$ F = \\frac{N_{\\mathrm{ss}}'}{N_{\\mathrm{ss}}} = \\frac{\\frac{\\alpha}{k'}}{\\frac{\\alpha}{k}} = \\frac{\\alpha}{k'} \\cdot \\frac{k}{\\alpha} = \\frac{k}{k'} $$\nThe deposition flux $\\alpha$ cancels out, as expected for a relative measure. The final step is to relate these rate constants to the provided half-lives, $t_{1/2}$ and $t_{1/2}'$, using the definition of half-life for exponential decay.\n\nFor a first-order decay process governed by $\\frac{dN}{dt} = -k_{\\mathrm{eff}} N$, the solution is $N(t) = N(0) \\exp(-k_{\\mathrm{eff}} t)$. The half-life, $t_{h}$, is the time at which $N(t_{h}) = \\frac{1}{2}N(0)$.\n$$ \\frac{1}{2}N(0) = N(0)\\exp(-k_{\\mathrm{eff}} t_{h}) $$\n$$ \\frac{1}{2} = \\exp(-k_{\\mathrm{eff}} t_{h}) $$\nTaking the natural logarithm of both sides:\n$$ \\ln\\left(\\frac{1}{2}\\right) = -k_{\\mathrm{eff}} t_{h} $$\n$$ -\\ln(2) = -k_{\\mathrm{eff}} t_{h} $$\nTherefore, the relationship between the rate constant and the half-life is:\n$$ k_{\\mathrm{eff}} = \\frac{\\ln(2)}{t_{h}} $$\nApplying this relationship to our two cases:\nThe rate constant without factor H is $k$, corresponding to the half-life $t_{1/2}$.\n$$ k = \\frac{\\ln(2)}{t_{1/2}} $$\nThe rate constant with factor H is $k'$, corresponding to the half-life $t_{1/2}'$.\n$$ k' = \\frac{\\ln(2)}{t_{1/2}'} $$\nFinally, we substitute these expressions for $k$ and $k'$ into our equation for the fold-change $F$.\n$$ F = \\frac{k}{k'} = \\frac{\\frac{\\ln(2)}{t_{1/2}}}{\\frac{\\ln(2)}{t_{1/2}'}} $$\nThe term $\\ln(2)$ cancels from the numerator and the denominator, yielding the simplest form for the expression.\n$$ F = \\frac{1/t_{1/2}}{1/t_{1/2}'} = \\frac{t_{1/2}'}{t_{1/2}} $$\nThis result is in terms of only the given half-lives, as required. Since factor H accelerates removal, $t_{1/2}' < t_{1/2}$, which correctly implies that $F < 1$.", "answer": "$$ \\boxed{\\frac{t_{1/2}'}{t_{1/2}}} $$", "id": "2879447"}, {"introduction": "Once inside a cell, a virus confronts a web of innate immune signaling pathways designed to trigger an antiviral state, primarily through the production of type I interferons. Effective viral antagonists do not strike randomly; they target the most critical nodes in this network. This problem [@problem_id:2879459] challenges you to analyze the strategic logic of a signaling pathway, comparing the efficacy of inhibiting a redundant kinase versus a non-redundant downstream bottleneck. This exercise moves beyond simple calculation to develop your intuition for pathway dynamics and the evolutionary rationale behind viral immune evasion tactics.", "problem": "A virus infecting human fibroblasts faces an innate immune system in which cytosolic pattern-recognition receptor signaling converges on adaptors that recruit and activate TANK-binding kinase $1$ (TBK$1$) to phosphorylate Interferon Regulatory Factor $3$ (IRF$3$), enabling IRF$3$ dimerization and nuclear translocation. In most non-plasmacytoid cells, basal Interferon Regulatory Factor $7$ (IRF$7$) is low, so the initial wave of type I interferon depends primarily on IRF$3$. Autocrine type I interferon signaling through the interferon-$\\alpha/\\beta$ receptor drives Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) activation, forming the interferon-stimulated gene factor $3$ (ISGF$3$) complex (STAT$1$/STAT$2$/IRF$9$), which amplifies the expression of interferon-stimulated genes (ISGs). In this cell type, adaptor proteins such as Stimulator of Interferon Genes (STING), Mitochondrial Antiviral-Signaling protein (MAVS), and TIR-domain-containing adapter-inducing interferon-$\\beta$ (TRIF) are present at low copy number relative to upstream receptors and downstream kinases, so adaptor availability is limiting for signal throughput.\n\nThe virus can encode one of two antagonists:\n- Antagonist $X$ binds TBK$1$ and prevents its activation-loop phosphorylation at Ser$172$ without degrading TBK$1$ or adaptors.\n- Antagonist $Y$ binds karyopherin-$\\beta$ (importin-$\\beta$) and specifically prevents nuclear import of phosphorylated IRF$3$ dimers, without affecting NF-$\\kappa$B or Mitogen-Activated Protein Kinase pathways.\n\nAssume the following foundational facts: \n- Kinase redundancy exists at the level of IRF$3$ phosphorylation (inhibitor of nuclear factor kappa-B kinase epsilon, IKK$\\varepsilon$, can phosphorylate IRF$3$ when appropriately scaffolded), whereas nuclear import of IRF$3$ dimers is obligatory for IRF$3$-dependent transcription. \n- NF-$\\kappa$B activation alone is not sufficient to drive interferon-$\\beta$ transcription in the absence of nuclear IRF$3$.\n- Under adaptor-limiting conditions, any residual kinase that can phosphorylate IRF$3$ must still be recruited or scaffolded through adaptor-associated complexes, but even a small number of IRF$3$ dimers that reach the nucleus can initiate the autocrine interferon amplification loop.\n\nWhich statement best contrasts the consequences of these two viral strategies and correctly infers which would more effectively blunt global ISG induction when adaptor abundance is limiting?\n\nA. Inhibiting TBK$1$ phosphorylation would be more effective because it prevents activation of both IRF$3$ and IRF$7$ across all adaptor platforms, completely abolishing type I interferon irrespective of adaptor limitation.\n\nB. Inhibiting IRF$3$ nuclear translocation would be more effective because it bypasses kinase-level redundancy (TBK$1$ and IKK$\\varepsilon$), blocking both the initial interferon-$\\beta$ wave and the interferon receptor–mediated amplification loop, which is especially critical when adaptor abundance is limiting.\n\nC. The two interventions are effectively equivalent for suppressing ISGs because they lie on a single linear pathway and therefore reduce output to the same extent under any adaptor abundance.\n\nD. When adaptor abundance is limiting, the rate-limiting step is upstream, so downstream perturbations such as blocking IRF$3$ nuclear import have little impact; therefore, inhibiting TBK$1$ phosphorylation is superior for suppressing ISGs.\n\nE. Blocking TBK$1$ phosphorylation preserves NF-$\\kappa$B activation, allowing interferon-$\\beta$ transcription to proceed; therefore, it is less effective than blocking IRF$3$ nuclear translocation.", "solution": "The problem statement is critically evaluated for validity before proceeding to a solution.\n\n### Step 1: Extract Givens\n- **Cellular Context**: Human fibroblasts.\n- **Signaling Pathway**: Cytosolic pattern-recognition receptor signaling converges on adaptors that recruit and activate TANK-binding kinase $1$ ($TBK1$).\n- **$TBK1$ Function**: Phosphorylates Interferon Regulatory Factor $3$ ($IRF3$).\n- **$IRF3$ Activation**: Phosphorylation enables $IRF3$ dimerization and nuclear translocation.\n- **Initial Interferon Wave**: Depends primarily on $IRF3$ due to low basal levels of Interferon Regulatory Factor $7$ ($IRF7$).\n- **Amplification Loop**: Autocrine type I interferon signaling through the interferon-$\\alpha/\\beta$ receptor activates Janus kinase ($JAK$) and Signal Transducer and Activator of Transcription ($STAT$), forming the interferon-stimulated gene factor $3$ ($ISGF3$) complex ($STAT1$/$STAT2$/$IRF9$).\n- **$ISGF3$ Function**: Amplifies expression of interferon-stimulated genes ($ISGs$).\n- **Rate-Limiting Step**: Adaptor proteins (Stimulator of Interferon Genes ($STING$), Mitochondrial Antiviral-Signaling protein ($MAVS$), TIR-domain-containing adapter-inducing interferon-$\\beta$ ($TRIF$)) are present at low copy number, making adaptor availability limiting for signal throughput.\n- **Antagonist $X$**: Binds $TBK1$ and prevents its activation-loop phosphorylation at Ser$172$. Does not degrade $TBK1$ or adaptors.\n- **Antagonist $Y$**: Binds karyopherin-$\\beta$ and specifically prevents nuclear import of phosphorylated $IRF3$ dimers. Does not affect $NF-\\kappa B$ or Mitogen-Activated Protein Kinase pathways.\n- **Foundational Fact 1**: Kinase redundancy exists; inhibitor of nuclear factor kappa-B kinase epsilon ($IKK\\varepsilon$) can also phosphorylate $IRF3$ when scaffolded.\n- **Foundational Fact 2**: Nuclear import of $IRF3$ dimers is obligatory for $IRF3$-dependent transcription.\n- **Foundational Fact 3**: $NF-\\kappa B$ activation alone is not sufficient to drive interferon-$\\beta$ transcription without nuclear $IRF3$.\n- **Foundational Fact 4**: Even a small number of nuclear $IRF3$ dimers can initiate the autocrine interferon amplification loop.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement describes a detailed, albeit simplified, immunological signaling scenario.\n- **Scientifically Grounded**: The pathway described—from PRR recognition to $TBK1$/$IKK\\varepsilon$ activation, $IRF3$ phosphorylation, interferon-$\\beta$ production, and JAK-STAT amplification—is a cornerstone of innate antiviral immunity. The roles of all mentioned proteins ($TBK1$, $IRF3$, $STING$, $MAVS$, $TRIF$, $IKK\\varepsilon$, $STATs$, etc.) are consistent with established molecular immunology. The concept of viral antagonists targeting specific nodes in this pathway is a central theme in virology.\n- **Well-Posed**: The problem sets up a clear comparison between two distinct viral strategies under a specified biophysical constraint (limiting adaptor concentration). The foundational facts provide the necessary rules to deduce a unique and meaningful answer regarding the relative efficacy of the two strategies.\n- **Objective**: The language is precise and technical. All statements are presented as facts within the context of the problem, free of subjectivity or ambiguity.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is a well-constructed, scientifically sound question that tests understanding of signaling pathway logic, redundancy, and rate-limiting steps. A solution will be derived.\n\n### Derivation of Solution\nThe central task is to compare the efficacy of two viral antagonists, $X$ and $Y$, in suppressing the host interferon response, under the critical condition that adaptor proteins are the limiting resource.\n\nThe pathway for the initial type I interferon response can be summarized as:\n$1$. Virus Detection $\\rightarrow$ Adaptor Scaffolding ($STING/MAVS/TRIF$)\n$2$. Adaptor Scaffolding $\\rightarrow$ Recruitment and activation of kinases ($TBK1$ or $IKK\\varepsilon$)\n$3$. Kinase Activation $\\rightarrow$ Phosphorylation of $IRF3$\n$4$. $IRF3$ Phosphorylation $\\rightarrow$ $IRF3$ Dimerization\n$5$. $IRF3$ Dimerization $\\rightarrow$ Nuclear Import via Karyopherin-$\\beta$\n$6$. Nuclear $IRF3$ $\\rightarrow$ Transcription of initial interferon-$\\beta$ ($IFN-\\beta$)\n$7$. $IFN-\\beta$ Secretion $\\rightarrow$ Autocrine signaling via $IFNAR$\n$8$. $IFNAR$ Signaling $\\rightarrow$ $JAK/STAT$ activation $\\rightarrow$ $ISGF3$ formation\n$9$. $ISGF3$ Formation $\\rightarrow$ Massive transcription of Interferon-Stimulated Genes ($ISGs$)\n\nLet us analyze the two antagonists in this context.\n\n**Analysis of Antagonist $X$:**\nAntagonist $X$ inhibits the activation of $TBK1$. However, the problem explicitly states that kinase redundancy exists: $IKK\\varepsilon$ can also phosphorylate $IRF3$ when appropriately scaffolded. Since Antagonist $X$ is specific for $TBK1$, it leaves the $IKK\\varepsilon$-mediated pathway intact. Because adaptors are limiting, only a small number of signaling complexes can form. Any of these complexes that recruit $IKK\\varepsilon$ instead of or in addition to $TBK1$ will be able to phosphorylate $IRF3$. The problem states that even a small number of phosphorylated $IRF3$ dimers reaching the nucleus is sufficient to initiate the powerful positive feedback amplification loop. Therefore, the inhibition provided by Antagonist $X$ is \"leaky\" due to kinase redundancy, and this leakiness is sufficient to trigger a full-blown response.\n\n**Analysis of Antagonist $Y$:**\nAntagonist $Y$ inhibits the nuclear import of phosphorylated $IRF3$ dimers. This step occurs downstream of $IRF3$ phosphorylation. Critically, the problem states this step is *obligatory* for $IRF3$-dependent transcription, and no redundancy for this import mechanism is mentioned. This means Antagonist $Y$ creates a complete bottleneck. It does not matter whether $IRF3$ was phosphorylated by $TBK1$ or by the redundant kinase $IKK\\varepsilon$; in either case, the resulting phosphorylated $IRF3$ dimer is blocked from entering the nucleus. By preventing nuclear entry of $IRF3$, Antagonist $Y$ completely prevents the initial transcription of $IFN-\\beta$. If the initial $IFN-\\beta$ wave is absent, the entire amplification loop involving $ISGF3$ and global $ISG$ induction cannot be initiated.\n\n**Comparison and Conclusion:**\nAntagonist $Y$ targets a downstream, non-redundant, obligatory step in the pathway. This provides a complete and robust blockade of the entire interferon response. Antagonist $X$ targets a step for which a redundant mechanism exists, making its blockade inherently incomplete or \"leaky\". Given that even a small signal can be massively amplified, a leaky inhibitor is far less effective than a complete one. Therefore, the strategy of blocking $IRF3$ nuclear import (Antagonist $Y$) is more effective at blunting global $ISG$ induction than blocking $TBK1$ activation (Antagonist $X$), especially under the specified condition of limiting adaptors.\n\n### Option-by-Option Analysis\n\n**A. Inhibiting $TBK1$ phosphorylation would be more effective because it prevents activation of both $IRF3$ and $IRF7$ across all adaptor platforms, completely abolishing type I interferon irrespective of adaptor limitation.**\nThis statement is incorrect. It fails to account for the specified kinase redundancy with $IKK\\varepsilon$, which can still phosphorylate $IRF3$ and, later, $IRF7$. Thus, the inhibition is not \"complete\". The claim of being \"irrespective of adaptor limitation\" is also contrary to the problem's emphasis.\n\n**Verdict: Incorrect**\n\n**B. Inhibiting $IRF3$ nuclear translocation would be more effective because it bypasses kinase-level redundancy ($TBK1$ and $IKK\\varepsilon$), blocking both the initial interferon-$\\beta$ wave and the interferon receptor–mediated amplification loop, which is especially critical when adaptor abundance is limiting.**\nThis statement is correct. It precisely identifies the crucial advantage of Antagonist $Y$'s mechanism: it targets a single, essential step downstream of the redundant kinases, thereby creating a complete blockade. It correctly links the prevention of the initial wave to the prevention of the amplification loop and correctly notes the heightened importance of a complete block when a weak initial signal (due to limiting adaptors) can still be amplified.\n\n**Verdict: Correct**\n\n**C. The two interventions are effectively equivalent for suppressing $ISGs$ because they lie on a single linear pathway and therefore reduce output to the same extent under any adaptor abundance.**\nThis statement is incorrect. The pathway is not \"single linear\" due to the parallel, redundant kinase activity of $IKK\\varepsilon$. Because one intervention targets a redundant step and the other targets a non-redundant one, their effects are not equivalent.\n\n**Verdict: Incorrect**\n\n**D. When adaptor abundance is limiting, the rate-limiting step is upstream, so downstream perturbations such as blocking $IRF3$ nuclear import have little impact; therefore, inhibiting $TBK1$ phosphorylation is superior for suppressing $ISGs$.**\nThis statement demonstrates flawed logic. While the adaptor concentration limits the *maximum rate* of signaling, it does not render downstream inhibition ineffective. On the contrary, because the amplification loop can be triggered by a very small signal, a complete block at a downstream chokepoint is the *most* effective strategy to prevent any signal from initiating this amplification. The conclusion that the perturbation has \"little impact\" is false.\n\n**Verdict: Incorrect**\n\n**E. Blocking $TBK1$ phosphorylation preserves $NF-\\kappa B$ activation, allowing interferon-$\\beta$ transcription to proceed; therefore, it is less effective than blocking $IRF3$ nuclear translocation.**\nThis statement contains faulty reasoning. While the conclusion that it is \"less effective\" is true, the reason provided is false. The problem explicitly states that \"$NF-\\kappa B$ activation alone is not sufficient to drive interferon-$\\beta$ transcription in the absence of nuclear $IRF3$\". Since both antagonists result in the absence of nuclear $IRF3$ (completely for $Y$, and largely for $X$), the fact that $NF-\\kappa B$ is active is irrelevant for $IFN-\\beta$ transcription in this context. The core reason for the difference in efficacy is kinase redundancy, not $NF-\\kappa B$ status.\n\n**Verdict: Incorrect**", "answer": "$$\\boxed{B}$$", "id": "2879459"}, {"introduction": "Some of the most successful pathogens evade immunity not by fighting the system head-on, but by constantly changing their appearance. This 'moving target' strategy, known as antigenic variation, is masterfully employed by parasites like *Trypanosoma brucei*. This advanced practice [@problem_id:2879483] guides you in modeling this dynamic process as a stochastic competition between pathogen innovation and immune clearance. You will derive the expected time to immune escape from first principles and then implement a computational solution, gaining valuable experience in the quantitative and computational methods used to study host-pathogen population dynamics.", "problem": "You are asked to transform a biological scenario of antigenic variation into a quantitatively precise, testable computation. In the protozoan parasite Trypanosoma brucei, immune evasion is mediated by switch among Variant Surface Glycoprotein (VSG) genes. Assume a Variant Surface Glycoprotein (VSG) archive of size $N$ possible antigenically distinct genes, a gene conversion rate $\\gamma$ per lineage per day that produces switching attempts, and an immune clearance rate $c$ per lineage per day for lineages expressing recognized VSGs. A recognized lineage here means parasites currently expressing a VSG that has been previously exposed to the immune system; such lineages are removed at rate $c$. A switching attempt yields a novel, unrecognized VSG with probability equal to the fraction of unused VSGs remaining, which at the start is $(N-1)/N$ if one VSG is already in use. Model the early dynamics as a linear birth–death–innovation process for the number of recognized lineages, where “birth” events correspond to successful innovations (appearance of a lineage expressing a previously unused VSG) and “death” events correspond to immune clearance of recognized lineages. Start with a single recognized lineage at time $t=0$.\n\nUsing only the following fundamental bases:\n- Antigen switching and immune clearance events can be modeled as independent Poisson processes with constant hazards for small time intervals (memoryless property).\n- In a linear birth–death process with per-lineage birth rate $b$ and per-lineage death rate $d$, the time to the first event (birth or death) from a starting population of one lineage is exponentially distributed with rate $b + d$.\n\nDefine the immune escape time $T$ as the time until the first successful innovation event occurs (i.e., the instant at which a lineage expressing a previously unused VSG appears). If immune clearance of the starting lineage occurs before any innovation, then immune escape never occurs, and the unconditional expected time to immune escape counts as $0$ contribution from those trajectories. Assume the archive is sufficiently large that depletion from a single successful innovation does not feed back before the first escape event; thus, at the start, the per-lineage innovation hazard is $b = \\gamma \\cdot \\frac{N-1}{N}$ and the per-lineage clearance hazard is $d = c$.\n\nTask:\n- Derive from first principles an explicit expression for the unconditional expected immune escape time $\\mathbb{E}[T]$ in days, expressed solely in terms of $N$, $\\gamma$, and $c$. Do not assume any additional model structure beyond what is stated above, and ensure your derivation identifies the role of the memoryless property and the law of total expectation.\n- Implement a program that computes $\\mathbb{E}[T]$ for a fixed test suite of parameter sets. All rates are per day, and the final answer must be given in days as floating-point numbers.\n\nTest suite (each triple is $(N, \\gamma, c)$, with $N$ unitless and $\\gamma$, $c$ in $\\text{day}^{-1}$):\n- Case A: $(N, \\gamma, c) = (1000, 0.02, 0.1)$\n- Case B: $(N, \\gamma, c) = (1, 0.1, 0.1)$\n- Case C: $(N, \\gamma, c) = (100, 0.0, 0.5)$\n- Case D: $(N, \\gamma, c) = (100, 0.5, 0.0)$\n- Case E: $(N, \\gamma, c) = (50, 0.05, 0.5)$\n- Case F: $(N, \\gamma, c) = (1000, 0.5, 5.0)$\n\nYour program should produce a single line of output containing the results as a comma-separated list enclosed in square brackets, in the same order as the test suite, where each entry is the computed $\\mathbb{E}[T]$ in days formatted as a floating-point number with exactly six digits after the decimal point. For example, a valid output format is $[x_1,x_2,x_3,x_4,x_5,x_6]$ where each $x_i$ is a float with six digits after the decimal point.", "solution": "The problem statement has been evaluated and is determined to be valid. It is scientifically grounded, self-contained, and quantitatively precise. It describes a classical competition between two stochastic processes, framed within a biologically relevant context. We may therefore proceed with a rigorous derivation.\n\nThe system begins at time $t=0$ with a single recognized parasite lineage. This lineage is subject to two independent, competing stochastic events, modeled as Poisson processes:\n$1$. **Successful Innovation (Birth):** The parasite switches to a novel, unrecognized Variant Surface Glycoprotein (VSG). This event corresponds to immune escape. The per-lineage rate for this event is designated as $b$.\n$2$. **Immune Clearance (Death):** The existing recognized lineage is destroyed by the host immune system. The per-lineage rate for this event is designated as $d$.\n\nThe problem provides the parameters to define these rates. The rate of switching attempts is $\\gamma$. The probability that a switch is successful (i.e., results in a novel VSG) is the fraction of unused VSGs in an archive of size $N$. With one VSG currently in use, this probability is $\\frac{N-1}{N}$. The simplifying assumption is made that this probability remains constant for the first event. Thus, the effective rate of successful innovation is:\n$$b = \\gamma \\cdot \\frac{N-1}{N}$$\nThe rate of immune clearance for a recognized lineage is given directly as $c$. Thus:\n$$d = c$$\n\nLet $T_b$ be the random variable for the time to the first innovation event, and $T_d$ be the random variable for the time to the first clearance event. Based on the Poisson process assumption, both are independent and exponentially distributed:\n- $T_b \\sim \\text{Exponential}(b)$\n- $T_d \\sim \\text{Exponential}(d)$\n\nThe immune escape time, $T$, is defined as the time of the first successful innovation. However, a crucial condition is imposed: if clearance occurs before innovation ($T_d < T_b$), the trajectory does not lead to immune escape, and its contribution to the unconditional expected time $\\mathbb{E}[T]$ is defined to be $0$. This means we are to calculate the expectation of a random variable $T_{eff}$ defined as:\n$$\nT_{eff} =\n\\begin{cases}\nT_b & \\text{if } T_b \\leq T_d \\\\\n0 & \\text{if } T_d < T_b\n\\end{cases}\n$$\nWe seek $\\mathbb{E}[T_{eff}]$. Using the law of total expectation, we can write:\n$$\\mathbb{E}[T_{eff}] = \\mathbb{E}[T_{eff} | T_b \\leq T_d] P(T_b \\leq T_d) + \\mathbb{E}[T_{eff} | T_d < T_b] P(T_d < T_b)$$\nFrom the definition of $T_{eff}$:\n- If $T_d < T_b$, then $T_{eff} = 0$, so its expectation is $\\mathbb{E}[0] = 0$. The second term vanishes.\n- If $T_b \\leq T_d$, then $T_{eff} = T_b$.\n\nThe expression thus simplifies to:\n$$\\mathbb{E}[T_{eff}] = \\mathbb{E}[T_b | T_b \\leq T_d] P(T_b \\leq T_d)$$\n\nWe proceed by calculating the two components of this product.\n\nFirst, the probability $P(T_b \\leq T_d)$ is the probability that an exponential random variable with rate $b$ is less than or equal to an independent exponential random variable with rate $d$. This is a standard result for competing exponential distributions:\n$$P(T_b \\leq T_d) = \\frac{b}{b+d}$$\nThis term represents the probability that the lineage successfully innovates before it is cleared.\n\nSecond, we must find the conditional expectation $\\mathbb{E}[T_b | T_b \\leq T_d]$. Let $T_{min} = \\min(T_b, T_d)$ be the time of the first event, whichever it may be. Due to the properties of independent exponential random variables, $T_{min}$ is also exponentially distributed with a rate equal to the sum of the individual rates:\n$$T_{min} \\sim \\text{Exponential}(b+d)$$\nThe expected time to this first event is therefore $\\mathbb{E}[T_{min}] = \\frac{1}{b+d}$.\nA fundamental consequence of the memoryless property of the exponential distribution is that the time of the first event, $T_{min}$, is independent of which event occurred first (i.e., whether $T_b \\leq T_d$ or $T_d < T_b$).\nGiven the condition $T_b \\leq T_d$, the time of innovation $T_b$ is precisely the time of the first event, $T_{min}$. Therefore:\n$$\\mathbb{E}[T_b | T_b \\leq T_d] = \\mathbb{E}[T_{min} | T_b \\leq T_d]$$\nDue to the independence of the time and identity of the first event, the conditioning on the identity does not alter the expectation of the time:\n$$\\mathbb{E}[T_{min} | T_b \\leq T_d] = \\mathbb{E}[T_{min}] = \\frac{1}{b+d}$$\nThis is the conditional expected time to escape, given that escape occurs.\n\nFinally, we combine these components to find the unconditional expectation as defined by the problem. The problem refers to this quantity as $\\mathbb{E}[T]$, so we adopt that notation.\n$$\\mathbb{E}[T] = \\left(\\frac{1}{b+d}\\right) \\cdot \\left(\\frac{b}{b+d}\\right) = \\frac{b}{(b+d)^2}$$\n\nSubstituting the expressions for $b$ and $d$ in terms of the given parameters $N$, $\\gamma$, and $c$:\n$$\\mathbb{E}[T] = \\frac{\\gamma \\frac{N-1}{N}}{\\left(\\gamma \\frac{N-1}{N} + c\\right)^2}$$\nThis is the final expression derived from first principles. It correctly evaluates to $0$ if innovation is impossible (i.e., if $\\gamma=0$ or $N=1$, which makes $b=0$). In the absence of immune clearance ($c=0$), the expression correctly simplifies to $\\mathbb{E}[T] = \\frac{1}{b}$, which is the mean time to the first innovation event, as escape is then guaranteed. The formula is robust and encapsulates the dynamics as specified.", "answer": "```python\nimport numpy as np\n\ndef solve():\n    \"\"\"\n    Computes the unconditional expected immune escape time for a series of test cases.\n    \"\"\"\n    # Test suite: each tuple is (N, gamma, c)\n    # N: size of VSG archive (unitless)\n    # gamma: gene conversion rate (per day)\n    # c: immune clearance rate (per day)\n    test_cases = [\n        (1000, 0.02, 0.1),  # Case A\n        (1, 0.1, 0.1),      # Case B\n        (100, 0.0, 0.5),    # Case C\n        (100, 0.5, 0.0),    # Case D\n        (50, 0.05, 0.5),    # Case E\n        (1000, 0.5, 5.0),   # Case F\n    ]\n\n    results = []\n    for case in test_cases:\n        N, gamma, c = case\n        \n        # Per-lineage innovation hazard (birth rate 'b').\n        # This is the product of the switching attempt rate (gamma) and the\n        # probability of choosing a novel antigen ((N-1)/N).\n        # We handle N=1, where (N-1)/N = 0, leading to b=0.\n        if N = 1:\n            b = 0.0\n        else:\n            b = gamma * (N - 1) / N\n        \n        # Per-lineage clearance hazard (death rate 'd').\n        d = c\n        \n        # The denominator of the derived formula is (b+d)^2.\n        # A denominator of zero occurs only if b=0 and d=0. In this case,\n        # the numerator b is also 0, and no event can occur. The escape\n        # probability is zero, so the expected time (as defined) is 0.\n        denominator = (b + d)**2\n        \n        if denominator == 0.0:\n            expected_time = 0.0\n        else:\n            # The derived expression for the unconditional expected immune escape time E[T]\n            # is b / (b + d)^2.\n            expected_time = b / denominator\n            \n        results.append(expected_time)\n\n    # Format the final output as a comma-separated list of floating-point numbers\n    # with six digits after the decimal point, enclosed in square brackets.\n    formatted_results = [f\"{res:.6f}\" for res in results]\n    print(f\"[{','.join(formatted_results)}]\")\n\nsolve()\n```", "id": "2879483"}]}